Emergent BioSolutions Reports First Quarter 2019 Financial Results
Reaffirms full year 2019 financial forecast and operational goals Provides Q2 2019 revenue forecast of $200M-$220M GAITHERSBURG, Md. , May 02, 2019 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc....
Emergent BioSolutions to Release First Quarter 2019 Financial Results and Conduct a Conference Call on May 2, 2019
GAITHERSBURG, Md. , April 18, 2019 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, May 2, 2019 at 5:00 pm (Eastern Time) to discuss the...
Emergent BioSolutions Announces Interim Results From Phase 2 Study Evaluating CHIKV-VLP, Chikungunya Virus Vaccine Candidate
GAITHERSBURG, Md. , April 16, 2019 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced results from the interim analysis of its Phase 2 clinical study evaluating the safety...
Emergent BioSolutions Initiates Phase 3 Clinical Study to Evaluate AV7909 for Post-Exposure Prophylaxis of Anthrax
GAITHERSBURG, Md. , March 19, 2019 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 3 trial to evaluate the lot consistency, immunogenicity,...
Emergent BioSolutions Awarded U.S. Department of State Contract to Supply Medical Countermeasures For Chemical Warfare Agents
GAITHERSBURG, Md. , Feb. 28, 2019 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has signed an indefinite-delivery, indefinite-quantity (IDIQ) contract with...
Emergent BioSolutions Reports Fourth Quarter and Full Year 2018 Financial Results
GAITHERSBURG, Md. , Feb. 21, 2019 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and year ended December 31, 2018 . FINANCIAL HIGHLIGHTS...
Emergent BioSolutions Announces Appointment of Seamus Mulligan to its Board of Directors
GAITHERSBURG, Md. , Feb. 12, 2019 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Seamus Mulligan to the company’s Board of Directors effective...
Emergent BioSolutions to Release Fourth Quarter and Full Year 2018 Financial Results and Conduct a Conference Call on February 21, 2019
GAITHERSBURG, Md. , Feb. 07, 2019 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 21, 2019 at 5:00 pm (Eastern Time) to discuss the...
Emergent BioSolutions Announces Appointment of Robert G. Kramer, Sr. to Its Board of Directors
GAITHERSBURG, Md. , Jan. 24, 2019 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Robert G. Kramer, Sr. to the company’s Board of Directors. Mr....
Emergent BioSolutions Announces Preliminary 2018 Financial Results and Provides 2019 Financial Forecast
Full year 2018 preliminary performance in line with recently revised guidance Full year 2019 forecast reflects continued growth of organic business and anticipated positive impact of recent...
Emergent BioSolutions Announces Daniel J. Abdun-Nabi to Retire as CEO; Robert G. Kramer, Sr. to Become President and CEO
GAITHERSBURG, Md. , Jan. 04, 2019 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced that its CEO Daniel J. Abdun-Nabi will be retiring and that its board of directors...
Emergent BioSolutions Announces Submission to FDA of Application Covering Emergency Use Authorization for NuThrax™
GAITHERSBURG, Md. , Dec. 28, 2018 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today the submission of an application to the U.S. Food and Drug Administration ( FDA ) for...